KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Net Cash Flow (2018 - 2025)

Esperion Therapeutics' Net Cash Flow history spans 8 years, with the latest figure at $75.4 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 171275.0% year-over-year to $75.4 million; the TTM value through Dec 2025 reached $23.1 million, down 63.06%, while the annual FY2025 figure was $23.1 million, 63.06% down from the prior year.
  • Net Cash Flow reached $75.4 million in Q4 2025 per ESPR's latest filing, up from $6.4 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $144.4 million in Q1 2024 to a low of -$87.0 million in Q1 2021.
  • Average Net Cash Flow over 5 years is -$6.9 million, with a median of -$25.5 million recorded in 2022.
  • Peak YoY movement for Net Cash Flow: tumbled 2299.2% in 2022, then skyrocketed 171275.0% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $105.2 million in 2021, then tumbled by 180.43% to -$84.6 million in 2022, then soared by 61.49% to -$32.6 million in 2023, then soared by 100.14% to $44000.0 in 2024, then surged by 171275.0% to $75.4 million in 2025.
  • Per Business Quant, the three most recent readings for ESPR's Net Cash Flow are $75.4 million (Q4 2025), $6.4 million (Q3 2025), and -$28.6 million (Q2 2025).